by Dr Sunil Upadhyay – Since the publication of the iPASS trial data, gefitinib has become the treatment of choice in EGFR mutation positive tumours. However, almost all… read more.
Foreward by Dr Sanjay Popat (pictured). The 14th Annual Scientific Meeting of the IASLC has now closed. Held in Amsterdam at the beginning of July 2011, the annual… read more.
Nephrotoxicity as the Primary Driver of Failure – Fact or Fiction? – Dr Philip Halloran, Alberta Applied Genomics Center, Alberta, Canada. The calcineurin inhibitors (CNIs), ciclosporin and tacrolimus,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
